OakChart

MediWound Ltd

MDWDHealthcare·Biotechnology·Israel·Micro·NASD·Nov 11 • 1:56 PM ET

13.77-0.34 (-2.37%)
2026-11-11 19:56 CET
Market cap
182.16 USD m
Revenue, TTM
11.86 USD m
Net income, TTM
-20.18 USD m
Free cash flow, TTM
-27.00 USD m
EPS diluted, TTM
-1.60
P/E
-
Compare

Price

MDWD against its 20, 50 and 200-day averages
2050200beatearnings
12.0014.0016.0018.00226K451KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MDWDclose 13.7820-day 13.0650-day 13.21200-day 15.0913.7852w low

30.1% under the 52-week high of 19.70 on 8 Jan 2026. 52-week low 11.80 on 26 Oct 2026. Last 15 sessions, 24.0% high to low

Profile

MDWD
52-week range, 25% of the way up
11.8019.70

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

IndexRUT
Employees121
IPOMar 20, 2014
Beta0.03
ATR, 14d0.62
Rel volume0.44
Short float18.61%
Insider own25.52%
Inst own53.70%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap177.84M
Enterprise Value152.04M
Income-20.18M
Sales11.86M
Book/sh2.76
Cash/sh2.74
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees121
IPOMar 20, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S14.99
P/B4.99
P/C5.03
P/FCF-
EV/EBITDA-
EV/Sales12.82
Quick Ratio2.09
Current Ratio2.32
Debt/Eq0.27
LT Debt/Eq0.24
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.60
EPS next Y-2.20
EPS next Q-0.71
EPS this Y-4.37%
EPS next Y-0.30%
EPS next 5Y16.86%
EPS past 3/5Y18.87% 2.36%
Sales past 3/5Y-13.82% -4.87%
EPS Y/Y TTM39.18%
Sales Y/Y TTM-40.26%
EPS Q/Q53.32%
Sales Q/Q-45.83%
EarningsNov 12 BMO
EPS/Sales Surpr.-1.09% 19.44%

Ownership

Insider Own25.52%
Insider Trans0.12%
Inst Own53.70%
Inst Trans-0.06%
ROA-29.06%
ROE-72.37%
ROIC-45.60%
Gross Margin15.46%
Oper. Margin-271.59%
Profit Margin-170.10%
SMA205.51%
SMA504.28%
SMA200-8.74%
Trades-

Technical

Shs Outstand12.91M
Shs Float9.62M
Short Float18.61%
Short Ratio16.53
Short Interest1.79M
52W High19.70 -30.08%
52W Low11.80 16.74%
Volatility6.58% 4.91%
ATR (14)0.62
RSI (14)54.87
Beta0.03
Rel Volume0.44
Avg Volume108.34K
Volume33,367

Performance

Perf Week-2.99%
Perf Month12.73%
Perf Quarter1.81%
Perf Half Y-15.23%
Perf YTD-25.38%
Perf Year-25.62%
Perf 3Y78.90%
Perf 5Y-38.31%
Perf 10Y-66.07%
Recom1.00
Target Price30.67
Prev Close14.11
Price13.77
Change %-2.37%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jun 02, 2025ResumedOOppenheimerOutperform$34+146.8%
May 02, 2025InitiatedAAlliance Global PartnersBuy$25+81.5%
Feb 28, 2025InitiatedCCraig HallumBuy$39+183.1%
Jul 16, 2024ReiteratedMMaxim GroupBuy$25 → $30+117.8%
Dec 22, 2022InitiatedMMaxim GroupBuy$11-20.1%
Jul 18, 2022ResumedOOppenheimerOutperform$7-49.2%
Sep 23, 2020InitiatedBBTIG ResearchBuy$6-56.4%
Nov 28, 2016InitiatedAAegis CapitalBuy$11-20.1%
Aug 17, 2016InitiatedWWells FargoOutperform
Apr 16, 2014InitiatedOOppenheimerOutperform$25+81.5%

Peers

Mkt cap
TickerCompanyMkt cap
VCELVericel Corp2.97B
RCELAVITA Medical Inc434.82M
MDXGMimedx Group Inc493.96M
ORGOOrganogenesis Holdings Inc133.05M
SMTISanara MedTech Inc291.07M
SNWVSanuwave Health Inc14.28M
IARTIntegra Lifesciences Holdings Corp1.17B
SNNSmith & Nephew plc ADR12.96B
ELUTElutia Inc41.63M
TELATELA Bio Inc40.12M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Rubinstein SamuelDirectorSep 01 '26Buy12.625256,626525Sep 02 04:02 PM
Rubinstein SamuelDirectorSep 01 '26Sale12.725256,6780Sep 02 04:02 PM
Hess ShmuelCOO & Chief Commercial OfficerAug 27 '26Sale12.923,95851,1490Aug 28 04:02 PM
Hess ShmuelCOO & Chief Commercial OfficerAug 26 '26Sale13.001,86524,2450Aug 28 04:02 PM
Shmulik HessOfficerAug 27 '26Proposed Sale12.703,95850,267Aug 28 06:36 AM
SHAMIR NACHUMDirectorJun 03 '26Buy14.006,00083,99655,815Jun 04 04:05 PM
Fox David MortonDirectorJun 01 '26Buy14.113,53749,90122,283Jun 02 07:30 AM
Rubinstein SamuelDirectorMay 29 '26Buy14.331502,1502,993Jun 01 07:00 AM
Hess ShmuelOfficerDec 02 '25Proposed Sale17.213,69363,557Dec 03 07:44 AM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
IZRLARK Israel Innovative Technology ETFAUM: 118.95M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWViShares Russell 3000 ETFAUM: 20.32B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

News

latest 14 of 200
  • After Smith+Nephew's $34 Billion Merger Collapse, This Wound Care Stock Is Worth a Look (NASDAQ: MDWD) (FinanceWire)
  • MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares (GlobeNewswire) -6.13% +6.90%
  • MediWound's Back-Half Revenue Ramp Faces Its First Real Test As VeriCell Deal Kicks In (Earnings Whispers) +6.05%
  • MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares (GlobeNewswire)
  • MediWound's EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus (Nasdaq: MDWD) (FinanceWire)
  • MediWound to Report Third Quarter 2026 Financial Results (GlobeNewswire)
  • Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) (FinanceWire)
  • MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid (GlobeNewswire)
  • Independent DSMB Recommends MediWound's EscharEx Phase III VALUE Study Continue Without Modification (GlobeNewswire) +5.87%
  • MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq: MDWD) (FinanceWire)
  • MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ... (GuruFocus.com)
  • MediWound: Q2 Earnings Snapshot (Associated Press)
  • MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.707--6.736
2026Q22026-08-13-0.770-0.762-0.6183.092.596
2026Q12026-05-27-0.230-0.653-0.2291.483.376
2025Q42026-03-05-0.560-0.650-0.5601.874.196
2025Q32025-11-20-0.240-0.812-0.2415.436.566
2025Q22025-08-14-1.230-0.573-1.2295.715.686
2025Q12025-05-21-0.070-0.662-0.0673.965.206
2024Q42025-03-19-0.360-0.576-0.3625.845.755
2024Q32024-11-26-0.980-0.477-0.9784.366.003
2024Q22024-08-14-0.680-0.420-0.6805.065.054
2024Q12024-05-29-1.050-0.407-1.0544.964.683
2023Q42024-03-21-0.190-0.263-0.1895.345.334
2023Q32023-11-21-0.240-0.443-0.2384.784.754
2023Q22023-08-150.100-0.4100.1004.774.184
2023Q12023-05-30-0.440-0.305-0.4403.805.164
2022Q42023-03-16-1.180-0.313-1.17811.626.604

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.2601.4341.27631.7930.43
2020FY-2.380-2.728-2.36621.7620.68
2021FY-3.500-3.433-3.48223.7623.85
2022FY-3.930-2.023-3.93026.5021.53
2023FY-0.750-0.798-0.74518.6918.67
2024FY-3.030-3.284-3.03520.2220.15
2025FY-2.100-2.162-2.10316.9618.12
2026FY--2.192--23.67
2027FY--2.198--31.81
2028FY--1.207--47.10
2029FY-0.533--104.41
2030FY-2.110--171.58

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-286006.735.658.20
2026Q3S2026-10-276016.735.658.20
2026Q3S2026-08-146066.735.658.20
2026Q3S2026-08-136156.945.658.43
2026Q3S2026-08-106108.706.7510.13
2026Q3S2026-06-016518.706.7510.13
2026Q3S2026-05-276418.676.7510.13
2026Q3S2026-05-246007.837.408.22
2026Q3S2026-05-206107.837.408.22
2026Q3S2026-05-196207.837.408.22
2026Q3S2026-03-106407.837.408.22
2026Q3S2026-03-096407.727.408.22
2026Q3S2026-03-066407.727.408.22
2026Q3S2026-03-056317.456.638.10

Estimate history

EPS, annual-6.65-0.2731.276-2.366-3.482-3.93-0.745-3.035-2.099-1.6037
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.68-0.978-0.362-0.067-1.229-0.241-0.56-0.229-0.574
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.4963.40131.78921.76323.76326.49618.68620.22216.95911.86
Period201720182019202020212022202320242025TTM
Sales, quarterly5.0634.3555.843.9555.7085.4291.8671.4753.092
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.8643.8833.8863.8913.8967.249.22210.79312.83512.91
Period201720182019202020212022202320242025MRQ
Shares, quarterly9.28610.78610.79311.25210.87612.82112.83512.84612.91
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue11.8616.9620.2218.6926.5023.7621.7631.793.40
Cost of Goods Sold Incl. D&A10.0314.8218.4415.7414.1815.6314.7512.492.19
Gross Profit1.832.131.782.9512.328.147.0119.301.21
Selling, General and Administrative Excl. Other34.0527.4121.1618.4519.9819.3615.8513.6411.96
Research and Development19.0313.498.257.079.619.907.354.634.02
Other Operating Expense0.000.000.000.000.000.000.00-0.00
Operating Income-32.22-25.28-19.38-15.50-7.66-11.22-8.845.67-10.75
Interest Expense-0.660.560.340.160.170.200.210.00
Unusual Expense0.00-1.7812.23-7.4210.060.59-0.431.69-6.78
Net Income Before Taxes-20.04-23.71-30.16-6.53-19.52-13.52-9.282.07-5.67
Income Taxes0.140.170.060.190.080.030.000.000.00
Consolidated Net Income-20.18-23.88-30.22-6.72-19.60-13.55-9.282.07-5.67
Net Income From Continuing Operations-20.18-23.88-30.22-6.72-19.60-13.55-9.282.07-5.67
Net Income-20.18-23.88-30.22-6.72-19.60-13.55-9.204.96-1.06
EPS (Recurring)-1.57-2.21-2.18-1.32-2.52-3.38-2.441.58-1.50
EPS (Basic, Before Extraordinaries)-1.60-2.10-3.03-0.75-3.93-3.48-2.371.28-0.27
EPS (Diluted)-1.60-2.10-3.03-0.75-3.93-3.48-2.371.28-0.27
EBITDA-30.33-23.57-17.90-14.20-6.39-9.98-7.756.82-10.17
Non-Operating Income (Expense)13.300.452.011.89-1.64-1.55-0.67-1.70-1.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.982.212.241.361.651.171.321.230.45
Price To Earnings Ratio-------17.00-
Price To Sales Ratio15.9612.388.774.912.542.714.632.6532.37
Gross Margin15.4612.598.8115.7746.5034.2432.2160.7235.58
Operating Margin-271.59-149.06-95.85-82.96-28.91-47.22-40.6217.82-315.97
Net Margin-170.10-140.80-149.46-35.94-73.97-57.03-42.2615.59-31.08
Shares Outstanding12.9112.8410.799.227.243.903.893.893.88
Market Capitalization182.16182.16192.0093.62549.5264.36100.7884.33110.35

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue3.091.481.875.435.713.965.844.36
Cost of Goods Sold Incl. D&A2.761.151.594.534.373.224.943.68
Gross Profit0.340.320.280.901.340.740.900.68
Selling, General and Administrative Excl. Other9.808.748.107.427.065.966.995.76
Research and Development5.905.194.483.473.492.892.992.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.46-8.42-7.82-6.53-5.72-5.22-6.08-5.08
Interest Expense1.12---7.99--5.18
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-7.36-2.97-7.11-2.60-13.28-0.72-3.89-10.26
Income Taxes0.03-0.020.070.050.040.010.020.02
Consolidated Net Income-7.39-2.95-7.18-2.65-13.32-0.73-3.91-10.28
Net Income From Continuing Operations-7.39-2.95-7.18-2.65-13.32-0.73-3.91-10.28
Net Income-7.39-2.95-7.18-2.65-13.32-0.73-3.91-10.28
EPS (Recurring)-0.57-0.23-0.56-0.24-1.23-0.07-0.36-0.98
EPS (Basic, Before Extraordinaries)-0.57-0.23-0.56-0.24-1.23-0.07-0.36-0.98
EPS (Diluted)-0.57-0.23-0.56-0.24-1.23-0.07-0.36-0.98
EBITDA-9.06-8.04-7.13-6.11-5.32-4.86-5.69-4.72
Non-Operating Income (Expense)3.225.450.713.930.434.502.190.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.530.450.470.530.610.600.590.75
Price To Sales Ratio15.9614.3213.969.4910.578.729.509.63
Gross Margin10.9021.9014.8916.5023.5118.6615.4615.55
Operating Margin-305.89-570.78-418.69-120.19-100.14-132.01-104.16-116.67
Net Margin-239.07-200.14-384.73-48.85-233.32-18.36-66.92-236.10
Shares Outstanding12.9112.8512.8412.8210.8811.2510.7910.79
Market Capitalization182.16206.94236.68194.75209.35174.63192.00194.80

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments53.1443.1641.7133.9011.0521.5829.4623.6336.07
Short Term Receivables2.375.854.429.532.272.844.347.272.77
Inventories4.092.692.851.961.201.381.611.681.89
Other Current Assets0.360.460.720.460.440.390.220.130.80
Total Current Assets59.9652.1649.7045.8414.9526.1935.6232.7141.52
Net Property, Plant & Equipment25.7920.8015.933.584.034.514.532.021.92
Total Investments and Advances0.440.440.440.180.190.000.000.000.00
Long-Term Note Receivable0.03-0.050.180.28----
Intangible Assets0.030.100.170.230.300.360.430.500.64
Other Assets0.000.000.180.000.000.000.010.050.06
Total Assets86.2673.5066.4650.0219.7431.0740.5935.2844.14
Short Term Debt Incl. Current Port. of LT Debt0.620.420.360.530.600.570.570.000.00
Accounts Payable3.614.105.535.664.692.994.072.723.25
Other Current Liabilities21.4822.034.945.875.434.715.742.182.18
Total Current Liabilities25.7126.5410.8312.0610.728.2710.374.905.43
Long Term Debt8.156.516.350.851.391.742.010.000.00
Provision for Risks Charges0.470.400.4615.970.290.290.240.350.33
Other Liabilities0.000.009.552.794.046.235.9913.4921.37
Total Liabilities34.3333.4627.1931.6616.4416.5318.6118.7427.14
Non-Equity Reserves8.298.897.687.457.897.276.817.577.38
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity43.6331.1531.6010.91-4.587.2715.178.979.62
Total Shareholders Equity43.6331.1531.6010.91-4.587.2715.178.979.62
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity43.6331.1531.6010.91-4.587.2715.178.979.62
Total Liabilities & Stockholders Equity86.2673.5066.4650.0219.7431.0740.5935.2844.14
Book Value Per Share3.402.893.431.51-1.181.873.902.312.49
Tangible Book Value Per Share3.402.883.411.48-1.251.783.792.182.33
Full-Time Employees121111100837775747376
Price to Book Ratio5.115.612.8447.40-14.0513.865.5612.3010.21
Return on Assets-29.90-43.19-11.53-56.19-53.34-25.895.45-14.27-36.38
Return on Equity-63.86-96.33-31.60-619.05-1,007.51-82.6717.12-60.94-167.14
Return on Invested Capital-46.11-80.24-17.70-166.66--102.0328.85-11.78-230.24
Quick Ratio2.171.864.333.641.283.003.286.347.30
Current Ratio2.331.974.593.801.393.173.436.687.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-20.36-23.88-30.22-6.72-19.60-13.55-9.204.96-1.06
Depreciation1.921.861.481.301.271.241.091.150.58
Other Funds (Non Cash)-7.902.7216.10-5.4413.763.271.55-2.12-10.56
Funds from Operations-26.34-19.30-12.64-10.85-4.57-9.04-6.563.98-11.04
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.824.771.272.34-7.240.16-0.064.49-1.01
Cash from Operating Activities-20.53-14.53-11.37-8.52-11.81-8.88-6.628.47-12.05
Capital Expenditures-6.48-5.51-6.27-6.46-0.56-0.49-0.92-0.79-0.53
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-0.03-14.04-4.38-29.800.004.0018.03-5.05-16.61
Purchase of Investments-14.48-14.04-4.38-29.800.000.000.00-5.05-16.61
Sale Or Maturity of Investments14.450.000.000.000.004.0018.030.000.00
Other Uses0.000.000.000.000.000.000.00-1.240.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-6.51-19.54-10.65-36.27-0.563.5117.11-7.08-17.15
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock31.9131.0523.3824.9138.390.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock31.9131.0523.3824.9138.390.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.010.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.00
Change in Long Term Debt0.000.000.000.000.000.000.00-0.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00-0.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.00
Net Financing Active Other Cash Flow-0.19-0.21-3.05-1.21-1.93-0.36-0.12-0.380.05
Other Financing Activities Uses-0.19-0.21-3.05-1.21-1.93-0.36-0.12-0.380.00
Cash from Financing Activities30.3329.6219.3922.9235.76-1.05-0.63-1.010.05
Exchange Rate Effect0.160.10-0.08-0.16-0.550.090.270.14-0.21
Net Change in Cash3.46-4.36-2.71-22.0322.85-6.3310.130.53-29.35
Free Cash Flow-27.00-20.04-17.64-14.98-12.37-9.37-7.547.68-12.57
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-------10.97-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments35.3444.6553.1459.0932.4438.27
Short Term Receivables3.492.752.376.046.805.18
Inventories4.124.774.094.413.843.58
Other Current Assets--0.36---
Total Current Assets42.9552.1759.9669.5343.0847.02
Net Property, Plant & Equipment28.3927.3325.7924.3823.3721.43
Total Investments and Advances0.450.000.440.000.450.00
Intangible Assets0.000.020.030.050.070.08
Other Assets0.000.000.000.000.000.48
Total Assets71.8879.9886.2694.4267.0069.02
Short Term Debt Incl. Current Port. of LT Debt0.930.930.621.060.820.69
Accounts Payable7.637.417.658.515.884.99
Other Current Liabilities9.9913.3117.4416.6922.3716.16
Total Current Liabilities18.5421.6525.7126.2529.0721.84
Long Term Debt8.618.138.158.278.076.42
Provision for Risks Charges0.300.300.470.460.480.43
Other Liabilities0.000.000.000.000.000.00
Total Liabilities27.4530.0734.3334.9837.6228.70
Non-Equity Reserves8.788.498.299.299.269.05
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity35.6441.4243.6350.1620.1231.27
Total Shareholders Equity35.6441.4243.6350.1620.1231.27
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity35.6441.4243.6350.1620.1231.27
Total Liabilities & Stockholders Equity71.8879.9886.2694.4267.0069.02
Book Value Per Share2.763.223.403.911.852.78
Tangible Book Value Per Share2.763.223.403.911.842.77
Full-Time Employees--121---
Price to Book Ratio5.114.744.729.746.975.38
Return on Assets-29.06-35.04-29.90-24.36-45.43-32.30
Return on Equity-72.37-71.82-63.86-48.83-148.65-77.92
Return on Invested Capital-16.71-5.96-13.87-4.54-47.25-1.93
Quick Ratio2.092.192.172.481.351.99
Current Ratio2.322.412.332.651.482.15

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.36-2.95-7.16-2.89-13.85-0.73
Depreciation0.400.380.690.440.420.36
Other Funds (Non Cash)-0.98-4.36-0.00-2.568.78-3.41
Funds from Operations-7.93-6.93-6.47-5.00-4.64-3.78
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.060.763.722.40-1.14-0.06
Cash from Operating Activities-8.99-6.18-2.75-2.60-5.79-3.84
Capital Expenditures-1.06-1.82-2.48-1.11-1.12-0.96
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-1.4619.00-22.414.845.75-2.65
Purchase of Investments0.000.00-14.480.002.65-2.65
Sale Or Maturity of Investments-1.4619.00-7.934.843.100.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.5217.18-24.893.734.62-3.61
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.760.00-1.2432.390.870.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.760.00-1.2432.390.870.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.080.00-0.11-0.00-0.11
Other Financing Activities Uses0.00-0.080.00-0.11-0.00-0.11
Cash from Financing Activities0.40-0.42-1.5831.930.56-0.36
Exchange Rate Effect0.11-0.030.060.010.000.02
Net Change in Cash-11.0110.55-29.1633.07-0.61-7.80
Free Cash Flow-10.06-8.00-5.23-3.71-6.91-4.80

Revenue breakdown

Medicinal Chemicals & Botanical Products2024: 20.22M 2025: 16.96M
Germany2024: 824.00K 2025: 817.00K
Italy2024: 817.00K 2025: 1.00M
Other countries2024: 2.28M 2025: 2.07M
Spain2024: 840.00K 2025: 1.29M
United States2024: 15.46M 2025: 11.78M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.61%1.8M9.6M94.27K
2026-10-1518.19%1.7M9.6M84.41K
2026-09-3019.18%1.8M9.6M85.56K
2026-09-1518.85%1.8M9.6M90.17K
2026-08-3116.92%1.6M9.6M86.37K
2026-08-1416.50%1.6M9.6M86.37K
2026-07-3116.85%1.6M9.6M89.11K
2026-07-1516.89%1.6M9.6M86.89K
2026-06-3017.04%1.6M9.6M94.97K
2026-06-1517.67%1.7M9.6M93.49K
2026-05-2917.00%1.6M9.6M89.37K
2026-05-1515.78%1.5M9.6M84.29K
2026-04-3015.99%1.5M9.6M85.25K
2026-04-1517.05%1.6M9.6M102.50K
2026-03-3117.63%1.6M8.8M100.01K
2026-03-1315.67%1.4M8.8M97.41K
2026-02-2715.79%1.4M8.8M99.71K
2026-02-1315.21%1.3M8.8M101.59K
2026-01-3014.54%1.3M8.8M95.37K
2026-01-1512.04%1.1M8.8M79.92K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call5.006.7011.000.0011.3760.000.000.929-0.1870.003
call6.005.7010.000.009.5650.000.000.905-0.1960.004
call7.004.709.000.008.1000.000.000.880-0.1990.004
call8.003.708.000.007.0310.000.000.854-0.2060.005
call9.002.757.000.006.0470.000.000.825-0.2020.006
call10.001.756.003.505.19711.000.000.792-0.1940.006
call11.000.755.002.404.46322.000.000.753-0.1830.007
call12.000.004.402.004.28911.000.000.707-0.1720.007
call13.000.003.600.003.4240.000.000.658-0.1510.008
call14.000.250.500.600.7386420.000.545-0.0850.009
call15.000.002.400.251.12215.000.000.423-0.0680.009
call16.000.002.350.001.4600.000.000.322-0.0640.008
call17.000.002.350.001.7460.000.000.286-0.0720.008
call18.000.002.350.001.9050.000.000.237-0.0720.007
call19.000.002.350.002.2220.000.000.244-0.0850.007
call20.000.002.350.002.4260.000.000.230-0.0900.007
call21.000.002.350.002.6130.000.000.219-0.0940.007
put5.000.002.350.0011.3970.000.00-0.071-0.1870.003
put6.000.002.350.009.6050.000.00-0.095-0.1960.004
put7.000.002.150.008.2040.000.00-0.118-0.1970.004
put8.000.002.350.007.4650.000.00-0.146-0.2060.005
put9.000.002.350.006.1050.000.00-0.173-0.1900.006
put10.000.002.350.003.7640.000.00-0.199-0.1260.006
put11.000.002.350.004.4950.000.00-0.244-0.1700.007
put12.000.002.400.002.5360.000.00-0.288-0.1030.007
put13.000.002.550.003.6180.000.00-0.340-0.1610.008
put14.000.002.601.001.66520.000.00-0.477-0.0550.009
put15.000.003.400.003.1560.000.00-0.612-0.0580.008
put16.000.054.500.003.6240.000.00-0.707-0.0560.007
put17.001.005.300.003.7130.000.00-0.741-0.0640.007
put18.002.006.300.004.0090.000.00-0.763-0.0690.007
put19.003.007.300.004.2920.000.00-0.780-0.0750.006
put20.004.008.300.004.5510.000.00-0.792-0.0770.006
put21.005.009.300.004.7680.000.00-0.803-0.0810.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-11-05424B5SEC
2026-11-03FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-11-03424B5SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-28SCHEDULE 13G/ASEC
2026-08-28144Filing for proposed sale of securities under Rule 144.SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-05-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-27SEC
2026-05-15SCHEDULE 13GSEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-04-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-02SEC
2026-03-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-30SEC
2026-03-253Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-096.63K16.68K1
2026-080075.39K2
2026-070000
2026-06133.90K200
2026-052.15K100
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
INVESTOR AB6.79%
Yelin Lapidot Holdings Management Ltd.5.87%
Rosalind Advisors, Inc.5.83%
PRICE T ROWE ASSOCIATES INC /MD/4.99%
BlackRock, Inc.4.09%
SPHERA FUNDS MANAGEMENT LTD.2.13%
Silverberg Bernstein Capital Management LLC1.83%
STATE STREET CORP1.31%
GEODE CAPITAL MANAGEMENT, LLC1.06%
Point72 Asset Management, L.P.1.01%

Funds

Fund% owned
Fidelity Series International Developed Markets Bond Index Fund317.69%
iShares Core International Aggregate Bond ETF145.69%
iShares 1-3 Year International Treasury Bond ETF73.97%
iShares International Treasury Bond ETF21.71%
State Street(R) SPDR(R) Bloomberg Short Term International Treasury Bond ETF14.00%
State Street(R) SPDR(R) Bloomberg International Treasury Bond ETF11.28%
Putnam Global Income Trust11.21%
Federated Hermes International Bond Strategy Portfolio4.96%
DFA INTERNATIONAL SMALL CAP VALUE PORTFOLIO3.48%
THE CONTINENTAL SMALL COMPANY SERIES2.96%

OakChart. MDWD. Cached 15 minutes.